<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> has been reported in a large variety of patients with <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Many case reports and reviews have appeared indicating that the presence of the <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> is related to thrombotic associations with the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) in a proportion of these patients </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the frequency of the thrombotic manifestations in 58 patients demonstrating <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and with a history of <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, including haematologic and lymphoproliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> were detected by clotting assay [<z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LAC)] or by enzyme-linked immunosorbent assay [anticardiolipin antibodies (aCL)] according to the Sapporo criteria </plain></SENT>
<SENT sid="4" pm="."><plain>Patients, 39/58, suffered from <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> and 19/58 patients from malignant haematologic or <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative diseases</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>One patient was suffering simultaneously from two <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> and a malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Among the patients with <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e>, 18/39 (46%) patients had thromboembolic complications of the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Among the patients with haematologic and lymphoproliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, only 6/19 (32%) suffered from thromboembolic complications </plain></SENT>
<SENT sid="8" pm="."><plain>There was, however, no relation between the titres of aCL antibodies and the clinical manifestations </plain></SENT>
<SENT sid="9" pm="."><plain>The presence, but not the titres, of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> may identify a subset of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients with a high risk of developing thrombotic complications </plain></SENT>
<SENT sid="10" pm="."><plain>The frequency of <z:mp ids='MP_0005048'>thrombosis</z:mp>, however, is lower in aPL-positive patients with lymphoproliferative and <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> </plain></SENT>
</text></document>